Your browser doesn't support javascript.
loading
Application Progress of Immune Checkpoint Inhibitors 
in Oncogene-driven Advanced Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer ; (12): 188-195, 2021.
Article in Zh | WPRIM | ID: wpr-880257
Responsible library: WPRO
ABSTRACT
With the development of precise medicine, targeted therapy has greatly improved the survival and prognosis of patients in advanced non-small cell lung cancer (NSCLC) with oncogenic drivers. However, no matter which kinds of targeted therapy are inevitable to develop therapeutic resistance, treatment options upon exhaustion of targeted therapies are limited. Immune checkpoint inhibitors (ICIs) can bring long-term survival to some patients with advanced NSCLC because of its unique long tailing effect. More and more studies have shown that ICIs can also benefit NSCLC patients with oncogenic drivers. However, the timing of ICIs intervention, the therapeutic regimen and the predictive biomarkers are actually debated, underscoring the need to explore the potential interest of ICIs in these populations.
.
Key words
Full text: 1 Index: WPRIM Language: Zh Journal: Chinese Journal of Lung Cancer Year: 2021 Type: Article
Full text: 1 Index: WPRIM Language: Zh Journal: Chinese Journal of Lung Cancer Year: 2021 Type: Article